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Background: Rosacea is an inflammatory skin disease. We examined the association between personal history of rosacea and risk
of incident cancers.
Methods: A total of 75 088 whites were included from the Nurses’ Health Study II (1991–2011). Information on clinician-diagnosed
rosacea and diagnosis year was collected in 2005. All cancers other than basal cell carcinoma (BCC) were confirmed.
Results: During 1 447 205 person-years, we identified 5194 cases with internal malignancies and 5788 with skin cancers. We did not
observe significant associations between personal history of rosacea and internal malignancies, except for thyroid cancer (hazard
ratio (HR)¼ 1.59, 95% confidence interval (CI)¼ 1.07–2.36). Among skin cancers, personal history of rosacea was associated with an
elevated risk of BCC (HR¼ 1.50, 95% CI¼ 1.35–1.67).
Conclusions: We suggest possible associations between personal history of rosacea and an increased risk of thyroid cancer and
BCC. Further studies are warranted to replicate our findings and to explore the underlying mechanisms.
Rosacea is a chronic inflammatory cutaneous disorder. Dysfunc-
tion in the innate and (or) adaptive immune response may
contribute to its pathophysiology (Elewski et al, 2011; Steinhoff
et al, 2013). Genetic predisposition, ultraviolet (UV) radiation,
psychological factors, Helicobacter pylori infection, and detrimental
lifestyles have been proposed as possible risk factors (Elewski et al,
2011; Steinhoff et al, 2013; Tan and Berg, 2013). This raises the
possibility that rosacea may be an end-organ response in a systemic
disorder.
Cancer is a major systemic disorder with imbalanced inflam-
matory and immune response as a hallmark (Moss and Blaser,
2005). Other overlapping risk factors also suggest a possible
association between rosacea and cancers. However, prior studies
linking rosacea to cancers have been very sparse (Margolin, 2004;
Friedman et al, 2006). We systemically examined the association
between a personal history of rosacea and risk of incident cancer,
based on a prospective analysis of the Nurses’ Health Study II
(NHS II). We comprehensively estimated the risk of the
subsequent risk of internal malignancies (non-skin cancers) and
skin cancers for women with rosacea.
MATERIALS AND METHODS
The NHS II began in 1989 when 116 430 US female nurses aged
25–42 years, completed a baseline questionnaire on medical history
and lifestyle practices (Supplementary Information). Biennially,
participants received a questionnaire and a response rate exceeding
90% has been achieved in the follow-up. Among participants with
information on personal history of rosacea, we excluded those with
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missing date of birth, all cancers at baseline, and all non-whites,
and 75 088 participants remained.
The main exposure is personal history of rosacea. In 2005, NHS
II participants responded to a question on whether they had
clinician-diagnosed rosacea and the diagnosis date if so (before
1991, 1991–1994, 1995–1998, 1999–2002, or 2003–2005).
Since 1989, participants have reported diagnoses of cancers,
including all internal malignancies, melanoma, and skin keratino-
cyte carcinoma (also known as non-melanoma skin cancer,
including squamous cell carcinoma (SCC) and basal cell carcinoma
(BCC)), on biennial surveys. Related medical records were
reviewed by physicians. Only pathologically confirmed invasive
cases were included, except for breast cancer and bladder cancer,
which included both invasive and in situ cases. For BCC, we did
not seek to obtain the medical records for all, but previous reports
have demonstrated a high validity of self-reports (Colditz et al,
1986; Hunter et al, 1992).
Statistical analysis. Person-years of follow-up were calculated
from the return of the 1991 questionnaire to the date of diagnosis
of the first internal (or skin) cancer, death, the last questionnaire
response, or June of 2011, whichever came first.
We calculated the hazard ratios (HRs) and 95% confidence
intervals (CIs) of major individual cancer (with 4100 incident
cases) using Cox proportional hazards models, stratified by 2-year
interval. Multivariate models were adjusted a priori for age, body
mass index, alcohol consumption, physical activity, physical
examination, multivitamin use, smoking status, oral contraceptive
use, menopausal status and postmenopausal hormone use, as well
as use of medications including tetracycline, isotretinoin, and
antibiotics (Supplementary information). For skin cancers and
breast cancer, we additionally adjusted for related risk factors (see
footnotes for Table 2 and Supplementary information). An
indicator was created for the missing data of each covariate as
appropriate. For individual cancers significantly associated with
personal history of rosacea, we conducted additional analyses
(online Supplementary Information)
Analyses were carried out by using SAS (version 9.2; SAS
Institute Inc., Cary, NC, USA). All P-values were two-tailed with
the significance level set at Po0.05.
RESULTS
Among 75 088 women, 6015 (8.0%) had been diagnosed with
rosacea as of 2005. Of them, 1064 had rosacea diagnosed before
1991. Women with rosacea were older and more likely to be
postmenopausal and have had benign breast diseases, but less likely
to be current smokers or current oral contraceptive users. Rosacea
cases reported less sun exposure but tended to expose more to
other skin cancer risk factors. Rosacea cases also reported an
increased history of severe teenage acne and use of tetracycline,
isotretinoin, or antibiotics (Table 1).
A total of 5194 internal cancer cases were identified within
1 447 205 person-years (1991–2011, Table 2). We did not find
significant association between a personal history of rosacea and
risk of incident total internal malignancies (HR¼ 1.08, 95%
CI¼ 0.96–1.22). For individual cancers, a personal history of
rosacea was significantly associated with increased risk of
incident thyroid cancer (HR¼ 1.59, 95% CI¼ 1.07–2.36), but
not with other individual cancers. Subgroup analysis for breast
cancer by subtypes or oestrogen receptor/progesterone receptor
status did not reach any significant findings either. For thyroid
cancer, further analyses did not change the results materially.
The HRs (95% CIs) were 1.58 (1.06–2.36) for the analysis
additionally adjusting for severe teenage acne, 1.53 (1.00–2.33)
for the analysis excluding those reporting a history of severe
teenage acne, 1.74 (1.03–2.97) for the analysis excluding those
using medications for acne or rosacea, 1.87 (1.24–2.79) for the
analysis excluding cases identified in the first follow-up period,
2.00 (1.23–3.25) for the analysis restricting the follow-up to
2005–2011, and 1.58 (1.06–2.36) for the analysis further adjusting
for history of SCC or BCC.
A total of 360 melanoma, 452 SCC, and 4976 BCC cases were
documented (1991–2011). A personal history of rosacea was
significantly associated with increased risk of incident BCC only
(HR¼ 1.50, 95% CI¼ 1.35–1.67), but not for melanoma or SCC
(Table 2). Baseline characteristics of all BCC cases identified during
the follow-up according to personal history of rosacea is shown in
Supplementary Table 1. Further analyses by adjusting for severe
teenage acne, excluding those with severe teenage acne, excluding
those using medications for acne or rosacea, excluding cases identified
in the first follow-up period, or restricting the follow-up starting at
2005 did not change the results materially (data not shown).
Table 1. Baseline characteristics of women according to
history of rosacea (1991)
Rosacea
Characteristicsa
No
(n¼74024)
Yes
(n¼1064)
Mean age, years (s.d.) 36.2 (4.7) 37.6 (4.1)
Height, m (s.d.) 1.6 (0.1) 1.7 (0.1)
Body mass index, kgm2 (s.d.) 24.5 (5.3) 25.0 (5.8)
Body mass index at age 18, kgm2 (s.d.) 21.2 (3.3) 21.2 (3.3)
Alcohol consumption, g per week (s.d.) 3.2 (6.2) 2.9 (5.3)
Physical activity, metabolic equivalent
hours per week (s.d.)
23.7 (60.2) 21.3 (53.2)
Multivitamin use, % 46.0 46.5
Physical examination, % 89.6 92.9
Current smoker, % 11.5 8.6
History of benign breast disease, % 34.6 39.7
Family history of breast cancer, % 6.0 6.5
Current oral contraceptive use, % 10.4 9.5
Postmenopausal women, % 7.2 8.3
Age at menarche, years (s.d.) 13.4 (1.4) 13.4 (1.4)
Age at first birth, years (s.d.) 25.8 (4.1) 26.0 (3.9)
Parity among parous women, times (s.d.) 1.6 (1.2) 1.5 (1.2)
Red or blonde hair colour, % 20.3 22.9
Five or more severe sunburns at ages
15–20 years, %
10.0 13.9
Childhood tendency to sunburns, % 48.1 55.3
Three or more moles on lower legs, % 32.4 36.0
Family history of melanoma, % 4.4 5.3
UV index of residence X7
At birth 18.9 20.6
At age 15 years 19.1 19.9
At age 30 years 25.4 25.8
Sun exposure X5h per week
College/high school 60.9 58.3
Age 25–35 years 50.9 48.9
Personal history of severe teenage acne, % 8.1 12.5
Antibiotics use for treatment of acne or
rosacea, %
6.9 41.0
Tetracycline use, % 1.7 6.8
Isotretinoin use, % 1.9 5.0
aVariables other than age are age adjusted.
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DISCUSSION
We systemically examined the association between personal history
of rosacea and risk of cancers during a follow-up of 20 years.
Women with a personal history of rosacea had a statistically
significantly elevated risk of thyroid cancer and BCC. The
association remained in the models controlling for the major
confounders. To our knowledge, our study is the first to reveal such
associations between rosacea and thyroid cancer and BCC.
In our study, thyroid cancer is the only individual internal
cancer significantly associated with rosacea. Thyroid cancer is
the most common endocrine malignancy, with ionising radiation
as a well-established risk factor (Boice, 2006; Li et al, 2012).
Accumulating evidence demonstrates that the inflammatory
response and immune function has a critical role in the
pathogenesis of thyroid cancer (Bozec et al, 2010; Guarino et al,
2010). Therefore, inflammation may be one potential link between
rosacea and thyroid cancer. It would be also important to examine
the side effect of skin radiotherapy, which has been used for
rosacea (Erceg et al, 2013).
Among skin cancers, BCC is the only one significantly
associated with rosacea. It is worth noting that rosacea cases
tended to have a higher UV exposure at early ages in our study. UV
radiation has an important role in rosacea development (Steinhoff
et al, 2013). The higher UV exposure among rosacea cases at early
ages might confer an elevated risk of BCC. The non-statistically
significant association in melanoma and SCC could be due to the
evidence that melanoma is more sensitive to intermittent UV
exposure and SCC is more sensitive to cumulative UV exposure
than to exposure at early ages (Wu et al, 2014).
Rosacea and acne are chronic inflammatory skin conditions that
share an inflammatory pathogenesis. Clinically, rosacea and acne are
quite distinct (Fleischer, 2011). Propionibacterium acnes is connected
with acne but not found to be involved in pathogenesis of rosacea.
Further analyses adjusting for history of severe teenage acne or
excluding those with severe teenage acne did not change the results
appreciably.
Our study has the following limitations. First, there may be
aetiologic heterogeneities underlying different types of rosacea. We
do not have information on the subtypes of rosacea and were not
able to examine the associations by rosacea subtypes. Second, all
study participants were women and Caucasians. Extrapolation of
our findings to men or other race/ethnicities should be approached
with caution, given the potentially different types of rosacea.
Third, our study is a prospective–retrospective mixed cohort study.
The self-reported personal history of rosacea in 2005 may have
introduced recall bias regarding the diagnosis. However, additional
analyses yielded robust findings. Moreover, because the partici-
pants are health professionals, a high validity of the rosacea self-
report is expected. Fourth, we did not seek for the medical records
for all BCC cases. However, the high levels of education and
familiarity with medical issues among the cohort members allows
high-quality and valid information to be collected on self-
administered forms. A previous validation study showed a
confirmation rate of 96% for BCC self-reports by histopathological
findings or medical records among a subgroup of women in NHS
(Colditz et al, 1986). Therefore, misclassification in BCC would be
expected to be minimal and would not bias any association
materially. The findings for BCC remained fairly robust in the
different sets of analysis, such as the lag analysis excluding the first
follow-up period and the analysis restricting the follow-up to 2005
and later. Therefore, the validity of the study findings was assuring.
Fifth, we do not have information on other therapies for rosacea
other than major medications, and are not able to evaluate the
possible effects of other treatment strategies, such as radiotherapy.
Sixth, we do not have access to the detailed histopathological
characteristics of thyroid cancer and therefore cannot explore in
depth the association with subtypes. Seventh, the concern over
multiple comparisons cannot be fully addressed.
In conclusion, our data suggest possible associations between
personal history of rosacea and an increased risk of thyroid cancer
and BCC. We provide evidence demonstrating that rosacea may
represent a systemic disorder beyond a skin condition. Further
studies are required to replicate our findings in other populations,
particularly those of women and non-Caucasians. It would be
critical to explore the potential heterogeneities for the association
with cancer in different subtypes of rosacea. Studies are warranted
to explore the underlying mechanisms for our findings. For
example, taking advantage of genome-wide association study and
next-generation sequencing techniques would be important to
identify potentially common genetic predisposition for inflamma-
tory skin disorders and cancers.
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Table 2. Personal history of rosacea and risk of incident cancer (1991–2011)
No Rosacea Rosacea Age-adjusted RR Multivariable-adjusted RRa
Internal malignancies 1382634 person-years 64571 person-years
Breast cancer 2998 186 1.07 (0.92–1.24) 1.03 (0.89–1.20)b
Thyroid cancer 331 29 1.54 (1.05–2.26)e 1.59 (1.07–2.36)e
Endometrial cancer 255 11 0.71 (0.38–1.29) 0.66 (0.35–1.22)
Colorectal cancer 215 12 0.87 (0.49–1.56) 0.85 (0.46–1.56)
Non-Hodgkin lymphoma 206 16 1.28 (0.77–2.14) 1.45 (0.85–2.45)
Ovarian Cancer 157 11 1.15 (0.62–2.13) 1.18 (0.63–2.23)
Other internal malignanciesc 720 47 1.10 (0.81–1.48) 1.19 (0.88–1.62)
Skin cancersd 1344071 person-years 60007 person-years
Melanoma 344 16 1.04 (0.63–1.72) 0.96 (0.57–1.62)
Squamous cell carcinoma 418 34 1.32 (0.93–1.88) 1.30 (0.90–1.88)
Basal cell carcinoma 4552 424 1.57 (1.42–1.73)e 1.50 (1.35–1.67)e
aAdjusted for age, body mass index (BMI), alcohol consumption, physical activity, physical examination, multivitamin use, smoking status, oral contraceptive use, menopausal status and
postmenopausal hormone use, as well as history of severe teenage acne, use of medications including tetracycline, isotretinoin and antibiotics.
bAdditionally adjusted for personal history of benign breast disease, family history of breast cancer, age at first birth and parity, age at menarche, height, and BMI at age 18 years.
cOther individual cancers each with cases o100.
dAdditionally adjusted for natural hair colour, childhood tendency to sunburn, number of sunburns at ages 15–20 years, family history of melanoma, self-reported mole count on lower legs, sun
exposures at high school and at age 25–35 years, and UV index at birth, age 15, and age 30 years.
ePo0.05.
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